Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
hyperlipoproteinemia type i
MeSH D008072 - hyperlipoproteinemia type i
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008052:
Inborn errors lipid metabolism
1 Company
1 Drug
$
Success rate
D006951:
Hyperlipoproteinemias
96 Companies
20 Drugs
$
Success rate
D008072:
Hyperlipoproteinemia type i
2 Companies
2 Drugs
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Akcea Therapeutics
Volanesorsen
Waylivra
2019-05-03
Uniqure
Alipogene tiparvovec
Glybera
2012-10-25
Clinical Trials
Historical Success Rate
Phase 1
0
%
0/0
Phase 2
89
%
8/9
Phase 3
20
%
2/10
Approved:
1
Overall Success rate:
0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Akcea Therapeutics
Volanesorsen
,
VUPANORSEN
Uniqure
Alipogene tiparvovec
,
Mycophenolate sodium
,
Solumedrol
,
Bolus
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use